Topoisomerase I Inhibitors
"Topoisomerase I Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds that inhibit the activity of DNA TOPOISOMERASE I.
| Descriptor ID |
D059004
|
| MeSH Number(s) |
D27.505.519.389.892.500 D27.505.954.248.794.500
|
| Concept/Terms |
Topoisomerase I Inhibitors- Topoisomerase I Inhibitors
- Inhibitors, Topoisomerase I
- Topoisomerase 1 Inhibitors
- Inhibitors, Topoisomerase 1
- DNA Topoisomerase I Inhibitors
- DNA Type 1 Topoisomerase Inhibitors
|
Below are MeSH descriptors whose meaning is more general than "Topoisomerase I Inhibitors".
Below are MeSH descriptors whose meaning is more specific than "Topoisomerase I Inhibitors".
This graph shows the total number of publications written about "Topoisomerase I Inhibitors" by people in this website by year, and whether "Topoisomerase I Inhibitors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2001 | 2 | 0 | 2 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2005 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2019 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Topoisomerase I Inhibitors" by people in Profiles.
-
A novel irinotecan-lipiodol nanoemulsion for intravascular administration: pharmacokinetics and biodistribution in the normal and tumor bearing rat liver. Drug Deliv. 2021 Dec; 28(1):240-251.
-
Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. Int J Gynecol Cancer. 2020 11; 30(11):1768-1774.
-
Sustained delivery of a camptothecin prodrug - CZ48 by nanosuspensions with improved pharmacokinetics and enhanced anticancer activity. Int J Nanomedicine. 2019; 14:3799-3817.
-
ATTAIN: Phase III study of etirinotecan pegol versus treatment of physician's choice in patients with metastatic breast cancer and brain metastases. Future Oncol. 2019 Jul; 15(19):2211-2225.
-
Integration of elicited expert information via a power prior in Bayesian variable selection: Application to colon cancer data. Stat Methods Med Res. 2020 02; 29(2):541-567.
-
Discovery and Mechanistic Study of Tailor-Made Quinoline Derivatives as Topoisomerase 1 Poison with Potent Anticancer Activity. J Med Chem. 2019 04 11; 62(7):3428-3446.
-
Pilot Study Comparing Systemic and Tissue Pharmacokinetics of Irinotecan and Metabolites after Hepatic Drug-Eluting Chemoembolization. J Vasc Interv Radiol. 2019 01; 30(1):19-22.
-
The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. J Natl Cancer Inst. 2018 07 01; 110(7):777-786.
-
Apoptotic capacity and risk of squamous cell carcinoma of the head and neck. Eur J Cancer. 2017 02; 72:166-176.
-
A Phase II Clinical Trial of CPI-613 in Patients with Relapsed or Refractory Small Cell Lung Carcinoma. PLoS One. 2016; 11(10):e0164244.